comparemela.com
Home
Live Updates
NeurAxis Stock Has 236% Upside Says GSCR Analyst, Fueled By Drug-Free IB-Stim Technology To Treat Pediatric Irritable Bowel Syndrome ($NRXS) : comparemela.com
NeurAxis Stock Has 236% Upside Says GSCR Analyst, Fueled By Drug-Free IB-Stim Technology To Treat Pediatric Irritable Bowel Syndrome ($NRXS)
According to an analyst at Goldman Smallcap Research, NeurAxis Inc. shares at current levels present a compelling investment opportunity. In fact, he models for a 12-month price target of $14 a...
Related Keywords
Boston
,
Massachusetts
,
United States
,
Rob Goldman
,
Jack Enterprises
,
Yahoo
,
Hawk Point Media Group Llc
,
Boston Scientific Corp
,
Neuraxis Inc
,
Goldman Smallcap Research
,
Smallcap Research
,
Stim Is Already Scoring
,
Stim To Target Post Concussion
,
Immediate Post Concussion Assessment
,
Post Concussion Symptom Scale
,
Balance Error Scoring Symptom
,
Big Pharma
,
Axis Is Deserving
,
Point Media Group
,
Eyed Jack Enterprises
,
Private Securities Litigation Reform Act
,
Hawk Point
,
Markets
,
comparemela.com © 2020. All Rights Reserved.